A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. There are many uncommon and rare mutations in the EGFR gene. The efficacy of the EGFR-TKIs is largely unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qi, Jiang, Mingyun, Li, Wenfei, Sun, Shuangli, Li, Jisheng, Stebbing, Justin, Liang, Xiaodong, Peng, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159765/
https://www.ncbi.nlm.nih.gov/pubmed/35664749
http://dx.doi.org/10.3389/fonc.2022.912426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159765/
https://www.ncbi.nlm.nih.gov/pubmed/35664749
http://dx.doi.org/10.3389/fonc.2022.912426

Ejemplares similares